These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 15185230)

  • 21. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
    Sakaguchi S; Sakaguchi N; Asano M; Itoh M; Toda M
    J Immunol; 1995 Aug; 155(3):1151-64. PubMed ID: 7636184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumor CD4 T-cell accumulation requires stronger priming than for expansion and lymphokine secretion.
    Joncker NT; Helft J; Jacquet A; Premel V; Lantz O
    Cancer Res; 2006 May; 66(10):5443-51. PubMed ID: 16707473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide.
    Grohmann U; Bianchi R; Fioretti MC; Fallarino F; Binaglia L; Uyttenhove C; Van Pel A; Boon T; Puccetti P
    Eur J Immunol; 1995 Oct; 25(10):2797-802. PubMed ID: 7589074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling the specific CD4+ T cell response against a tumor neoantigen.
    Flament H; Alonso Ramirez R; Prémel V; Joncker NT; Jacquet A; Scholl S; Lantz O
    J Immunol; 2015 Apr; 194(7):3501-12. PubMed ID: 25732731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine.
    Comes A; Rosso O; Orengo AM; Di Carlo E; Sorrentino C; Meazza R; Piazza T; Valzasina B; Nanni P; Colombo MP; Ferrini S
    J Immunol; 2006 Feb; 176(3):1750-8. PubMed ID: 16424205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Changes of regulatory T cell number in hepatocellular carcinoma-bearing mice and its relationship with tumor growth].
    Zhang P; Zhang LN; Zhu FL; Wang Q; Wang XY; Li HY; Liu CM; Gao F; Liu CH
    Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):342-5. PubMed ID: 17892128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
    Onizuka S; Tawara I; Shimizu J; Sakaguchi S; Fujita T; Nakayama E
    Cancer Res; 1999 Jul; 59(13):3128-33. PubMed ID: 10397255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
    Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
    Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    Shimizu J; Yamazaki S; Sakaguchi S
    J Immunol; 1999 Nov; 163(10):5211-8. PubMed ID: 10553041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
    Viehl CT; Moore TT; Liyanage UK; Frey DM; Ehlers JP; Eberlein TJ; Goedegebuure PS; Linehan DC
    Ann Surg Oncol; 2006 Sep; 13(9):1252-8. PubMed ID: 16952047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses.
    Roberts LK
    J Immunol; 1986 Mar; 136(5):1908-16. PubMed ID: 2936813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
    Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F
    Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors.
    El Andaloussi A; Han Y; Lesniak MS
    J Neurosurg; 2006 Sep; 105(3):430-7. PubMed ID: 16961139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
    Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
    Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
    Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
    Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
    Sun Z; Chen F; Meng F; Wei J; Liu B
    Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
    Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
    J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infiltration of a mesothelioma by IFN-gamma-producing cells and tumor rejection after depletion of regulatory T cells.
    Rudge G; Barrett SP; Scott B; van Driel IR
    J Immunol; 2007 Apr; 178(7):4089-96. PubMed ID: 17371963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of antigen-specific regulatory T cells in the liver-draining celiac lymph node following oral antigen administration.
    Hultkrantz S; Ostman S; Telemo E
    Immunology; 2005 Nov; 116(3):362-72. PubMed ID: 16236126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.